- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00762281
Safety and Effectiveness Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Hyperopia
August 9, 2012 updated by: Carl Zeiss Meditec, Inc.
A Prospective, Randomized, Multicenter Trial To Evaluate The Safety And Effectiveness Of The MEL 80 Excimer Laser Using LASIK (Laser In Situ Keratomileusis) For The Correction Of ≤ +6.0 D Of Hyperopia With Or Without Astigmatism Of +0.50 D To +3.50 D And MRSE ≤ +6.50 D
The purpose of this study is to determine whether the MEL 80 Excimer Laser is effective in the treatment of hyperopia, when used as part of the Laser In Situ Keratomileusis (LASIK) procedure.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
LASIK has become one of the most common refractive eye procedures performed in the country.
In the hyperopia procedure, a steepening occurs on the corneal surface, rather than the flattening procedure (myopic treatment).
The surgeon will produce a standard keratomileusis flap using a microkeratome, exposing the corneal stroma.
Recontouring under the flap is then accomplished by the removal of tissue from the stroma with the laser.
This recontouring results in an altering of effective lens power of the central cornea, measured in diopters (D).
The MEL 80 Excimer Laser System will be evaluated for its ability to create accurate and stable hyperopic refractive correction results.
Study Type
Interventional
Enrollment (Actual)
189
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Diego, California, United States, 92106
- US Navy Refractive Surgery Center
-
-
Colorado
-
Greenwood Village, Colorado, United States, 80111
- Dishler Laser Institute
-
-
Missouri
-
Kansas City, Missouri, United States, 64055
- Discover Vision Centers
-
-
Oregon
-
Eugene, Oregon, United States, 97401
- Fine, Hoffman, and Packer
-
-
Texas
-
Austin, Texas, United States, 78746
- Texan Eye Care
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53717
- Davis Duehr Dean Eye Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Naturally occurring hyperopia up to +6.0 D, with or without astigmatism of +0.50 D to +3.50 D at the spectacle plane, and MRSE ≤ +6.50 D;
- Have ≤ 0.75 D of latent hyperopia as determined by the difference between the preoperative MRSE and CRSE;
- A stable refraction for at least the last 12 months as documented by previous clinical records, i.e., the spherical and cylindrical portions of the manifest refraction have not progressed at a rate of more than 0.50 D during the year prior to the baseline examination in the eye to be treated;
- Hard contact lens wearers must have two central keratometry readings and two manifest refractions taken at least one week apart that do not differ by more than 0.50 D;
- Visual acuity correctable to at least 20/40 in both eyes;
- Operative eye must be targeted for emmetropia;
- At least 21 years of age;
- Willing and able to return for scheduled follow up examinations for 24 months after surgery;
- Sign and be given a copy of the written Informed Consent form.
Exclusion Criteria:
- A history of anterior segment pathology, including cataracts (in the operative eye);
- Severe dry eye syndrome unresolved by treatment;
- Residual, recurrent, active ocular or uncontrolled eyelid disease, corneal scars within the ablation zone or other corneal abnormality such as recurrent corneal erosion or severe basement membrane disease;
- Ophthalmoscopic signs of keratoconus (or keratoconus suspect);
- An ablation deeper than 250 microns from the corneal endothelium;
- Irregular or unstable (distorted/not clear) corneal mires on central keratometry readings;
- Blind in the fellow eye;
- Undergone previous intraocular or corneal surgery of any kind in the operative eye(s), including any type of excimer laser surgery for either refractive or therapeutic purposes;
- A history of ocular Herpes zoster or Herpes simplex keratitis;
- A history of steroid-responsive rise in intraocular pressure, glaucoma, or preoperative IOP >21 mm Hg;
- Diabetes, diagnosed autoimmune disease, connective tissue disease, or clinically significant atopic syndrome;
- Immunocompromised or use chronic systemic corticosteroid or other immunosuppressive therapy;
- Pregnant, lactating, or be of childbearing potential and not practicing a medically approved method of birth control;
- A known sensitivity to planned study medications;
- Participating in any other ophthalmic drug or device clinical trial during the time of this clinical investigation;
- At risk for angle closure or for developing strabismus postoperatively.
- For Fellow (Second) Eyes in Simultaneous Bilateral Treatment Procedures
- 1. Flap complications during the first eye's surgery such as a free cap, partial flap, thin flap, or irregular flap.
- 2. Epithelial defect exceeding 2 mm x 2 mm in dimension, or clinically significant debris in the interface between the flap and underlying stroma for the first eye.
- 3. Severe blepharospasm in the first eye that may have prevented or impeded the completion of the keratectomy and/or the laser ablation procedure.
- 4. Poor subject cooperation with instructions for the first eye's surgery and/or poor subject fixation on the laser fixation target.
- 5. Aborted LASIK procedure in the first eye or PRK was performed in the first eye because LASIK was not possible.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Treatment of Hyperopic LASIK
Treatment of Hyperopic corrections ≤ +6.0 D with or without Astigmatism of +0.50 to +3.50 D and MRSE ≤ +6.50 D.
|
Treatment of Hyperopic corrections ≤ +6.0 D with or without Astigmatism of +0.50 to +3.50 D and MRSE ≤ +6.50 D.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
At the point of stability, a minimum of 75% of eyes should have an achieved refraction within ± 1.00 D of the intended outcome, and at least 50% of eyes should be within ± 0.50 D of the intended outcome.
Time Frame: Point of stability
|
Point of stability
|
A minimum of 95% of eyes should have a change of < 1.00 D in manifest refraction spherical equivalent (MRSE) between 2 refractions performed at least 3 months apart, and the mean rate of MRSE change per month should be < 0.04 D.
Time Frame: Point of stability
|
Point of stability
|
A minimum of 85% of eyes targeted for emmetropia should have an uncorrected visual acuity of 20/40 or better at the postoperative interval at which stability has been established.
Time Frame: Point of stability
|
Point of stability
|
75% of eyes undergoing astigmatic treatment should be within ± 1.00 D of the attempted astigmatism correction by the point of stability.
Time Frame: Point of stability
|
Point of stability
|
Distance BSCVA of worse than 20/40 at the postoperative interval at which stability has been established should occur in less than 1.0% of eyes that had a BSCVA of 20/20 or better before surgery.
Time Frame: Point of stability
|
Point of stability
|
Loss of more than 2 lines of BSCVA should occur in less than 5.0% of eyes.
Time Frame: Point of stability
|
Point of stability
|
Less than 5% of eyes treated for sphere only should have a magnitude of postoperative manifest refractive astigmatism that varies from baseline cylinder by greater than 2.00 D at the postoperative interval at which stability has been established.
Time Frame: Point of stability
|
Point of stability
|
Incidence of Adverse Events to occur in less 1% of eyes
Time Frame: Postoperative visits
|
Postoperative visits
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Subject Satisfaction: As measured by a subjective questionnaire, and will be considered as a secondary efficacy variable.
Time Frame: Postoperative visits 3, 6, 9, 12, 18 and 24 months
|
Postoperative visits 3, 6, 9, 12, 18 and 24 months
|
Incidence of Complications
Time Frame: Postoperative visits
|
Postoperative visits
|
Patient Symptoms: As measured by a subjective questionnaire, will be considered as a secondary safety variable.
Time Frame: Preoperative and Postoperative visits 3, 6, 9, 12, 18 and 24 months
|
Preoperative and Postoperative visits 3, 6, 9, 12, 18 and 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: John Doane, MD, Discover Vision Centers
- Principal Investigator: Richard Hoffman, MD, FIne, Hoffman, and Packer LLC
- Principal Investigator: Howard Fine, MD, FIne, Hoffman, and Packer LLC
- Principal Investigator: Mark Packer, MD, FIne, Hoffman, and Packer LLC
- Principal Investigator: David Tanzer, MD, US Navy Refractive Surgery Center, San Diego, CA
- Principal Investigator: John Vukich, MD, Davis Duehr Dean Eye Clinic
- Principal Investigator: Jon Dishler, MD, Dishler Laser Institute
- Principal Investigator: Steven Dell, MD, Texan Eye Care
- Principal Investigator: Steve Schallhorn, MD, US Navy Refractive Surgery Center, San Diego, CA
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2004
Primary Completion (Actual)
October 1, 2006
Study Completion (Actual)
October 1, 2008
Study Registration Dates
First Submitted
September 26, 2008
First Submitted That Met QC Criteria
September 26, 2008
First Posted (Estimate)
September 30, 2008
Study Record Updates
Last Update Posted (Estimate)
August 13, 2012
Last Update Submitted That Met QC Criteria
August 9, 2012
Last Verified
August 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MEL 80-2004-2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperopia
-
Bausch & Lomb IncorporatedCompletedMyopia and Hyperopia and PresbyopiaUnited States
-
Lee, Steven, M.D.CompletedMyopia, | Hyperopia, | Astigmatism, | Presbyopia, | Eye Strain,
-
Donald O Mutti, OD, PhDCompleted
-
Jaeb Center for Health ResearchNational Eye Institute (NEI); Pediatric Eye Disease Investigator GroupCompleted
-
University Hospital, ToulouseCentre de Référence National du KératocôneTerminated
-
Medipol UniversityCompleted
-
University of Sao PauloCompleted
-
Alcon ResearchEnrolling by invitation
-
Coopervision, Inc.CompletedMyopia | HyperopiaSpain
Clinical Trials on MEL 80 Hyperopic LASIK Treatment
-
Abbott Medical OpticsCompletedHyperopiaUnited States
-
Carl Zeiss Meditec, Inc.CompletedMixed AstigmatismUnited States
-
Carl Zeiss Meditec, Inc.Completed
-
Technolas Perfect Vision GmbHUnknownHyperopic PresbyopiaIreland
-
Yungjin Pharm. Co., Ltd.CompletedChronic Obstructive Pulmonary DiseaseUnited States
-
Clinical Research Consultants, Inc.Alcon Research; WaveLight AGCompletedMyopia | HyperopiaUnited States
-
CTI BioPharmaCovanceCompleted
-
Novartis PharmaceuticalsCompletedAsthmaGermany, Netherlands, United Kingdom